See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. As with any medication, safety is a concern, particularly for seniors who may have additional health issues or be taking other medications.

According to the drug's manufacturer, Novartis, Cosentyx has a well-established safety profile in clinical trials, which included patients aged 65 and older [2]. However, as with any medication, Cosentyx can cause side effects. Common side effects include cold symptoms, stomach pain, and diarrhea [1].

It is important to note that, like many medications, Cosentyx can affect the immune system, making users more susceptible to infections [1]. This is particularly important for seniors, who are already at a higher risk of infection due to age-related changes in the immune system [3].

Furthermore, Cosentyx can interact with other medications, which can increase the risk of side effects or reduce the medication's effectiveness [1]. Therefore, it is crucial for seniors taking Cosentyx to inform their healthcare provider of all medications and supplements they are taking.

In terms of cost, Cosentyx can be expensive, with the list price for a typical course of treatment ranging from $20,000 to $30,000 per year [4]. However, there are programs available to help reduce the cost for eligible patients [2].

In summary, while Cosentyx has a well-established safety profile and is generally considered safe for seniors, it is important for seniors taking Cosentyx to be aware of the potential side effects and interactions with other medications. Additionally, seniors should inform their healthcare provider of all medications and supplements they are taking and discuss any concerns they may have.

Sources:

1. Cosentyx (secukinumab) [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
2. Cosentyx Savings Program. Novartis Pharmaceuticals Corp; 2021. Available from: <https://www.cosentyx.com/cost-and-coverage>.
3. Centers for Disease Control and Prevention. Influenza and Older Adults. Available from: <https://www.cdc.gov/flu/highrisk/olderadults.htm>.
4. DrugPatentWatch. Cosentyx (secukinumab) Psoriasis Pipeline & Clinical Trials Report 2022. Available from: <https://www.drugpatentwatch.com/drug/cosentyx>.